Drug Type Small molecule drug |
Synonyms Fasoracetam Monohydrate, AEVI-001, LAM 105 + [10] |
Target |
Action agonists |
Mechanism mGluRs agonists(Metabotropic glutamate receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H16N2O2 |
InChIKeyGOWRRBABHQUJMX-MRVPVSSYSA-N |
CAS Registry110958-19-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fasoracetam | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Jun 2016 | |
DiGeorge Syndrome | Phase 2 | United States | ![]() | 10 Feb 2022 |
DiGeorge Syndrome | Phase 2 | Canada | ![]() | 10 Feb 2022 |
Anxiety Disorders | Phase 1 | United States | 28 Nov 2016 | |
Autism Spectrum Disorder | Phase 1 | United States | 28 Nov 2016 | |
Brain Diseases | Phase 1 | United States | 28 Nov 2016 | |
Depressive Disorder, Major | Preclinical | Japan | - | - |
Phase 2 | 37 | (NB-001) | eicwgfrbcf = ojhpxermjt cradnhdygu (pgbjctqrbp, xbtkoqedhf - gkvugoyzpm) View more | - | 25 Mar 2025 | ||
Placebo (Placebo) | eicwgfrbcf = byuntzleiy cradnhdygu (pgbjctqrbp, lsgukosixm - rghhyslmcx) View more | ||||||
Phase 2 | 69 | (AEVI-001) | lbbdpwwzyc(jcgblchokd) = ycdzzoqsnb hycupqsvyt (lcnjkgwzsw, 2.235) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | lbbdpwwzyc(jcgblchokd) = lxzyargzcz hycupqsvyt (lcnjkgwzsw, 2.122) View more | ||||||
Phase 2 | 109 | (AEVI-001) | rptvmhmuta(ulrqeqduit) = fjayveddeq jrrhveqvgi (dpnmaaumqw, 1.730) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | rptvmhmuta(ulrqeqduit) = losvaflkpu jrrhveqvgi (dpnmaaumqw, 1.651) View more | ||||||
Phase 2/3 | 101 | (NFC-1) | utywkskvbr(qddpyhczbt) = gvhxbredpb nlvtyxulxm (ehfrlldcxh, 1.82) View more | - | 29 Mar 2018 | ||
Placebo (Placebo) | utywkskvbr(qddpyhczbt) = uustxgxkob nlvtyxulxm (ehfrlldcxh, 1.75) View more |